📋 Tender Overview
Preventing And Delaying The Development Of Diabetes In Africa: A Randomised Placebo -Controlled Double-Blind Phase Iii Trial Of Metformin In Hiv-Infected Persons With Pre-Diabetes
Tackling Diabetes In People Living With Hiv In Tanzaniadiabetes Is A Common And Serious Co-Morbidity Among People Living With Hiv, Increasing Their Risk Of Complications And Affecting Their Quality Of Life. Managing This Dual Health Burden Is Challenging, Especially In Resource-Limited Settings. The Covid-19 Pandemic Complicated Care By Decentralising Hiv Services To Community Posts And Impeding Patient Recruitment For Research. In This Context, The Eu-Funded Meta Trial Project Began In October 2021 In Dar Es Salaam, Tanzania, To Assess If Metformin Can Prevent Diabetes In Hiv-Positive Individuals With Pre-Diabetes. This Phase Iii Placebo-Controlled Trial Aims To Enrol 2 100 Participants And Provide Critical Data By 2025, Potentially Informing Global Health Strategies. Preliminary Results Show Reductions In Glucose Levels And Weight.
Funded Under
Health
Total Cost
€ 1 811 067,50
Eu Contribution
€ 1 811 067,50
Coordinated By
Fundacion Privada Instituto De Salud Global Barcelona
Spain
Start Date
1 January 2025
End Date
31 December 2026
